MedTrace Logo

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection

NCT07786779 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-26

No results posted yet for this study

Summary

A phase 1 study to evaluate the safety and tolerability of a single administration of YKYY033 injection in healthy adult participants

Conditions

  • Venous Thromboembolism (VTE)

Interventions

DRUG

YKYY033 Injection

subcutaneous injection, a single subcutaneous injection of the corresponding dose of YKYY033 injection

DRUG

YKYY033 Placebo

subcutaneous injection, a single subcutaneous injection of the corresponding dose of YKYY033 Placebo

Sponsors & Collaborators

  • Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-10
Primary Completion
2027-11-10
Completion
2028-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07786779 on ClinicalTrials.gov